EFV/FTC/TDF

ApprovedSmall molecule

Gilead

EFV/FTC/TDF is one of 16 small molecule programs targeting Cognitive Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive DisorderActive, not recruiting

Cognitive DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Cognitive Disorder

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Namenda

AbbVie

Phase 3

1 4

Paxil

SSebela Pharmaceuticals Development LLC

Phase 2

1 5

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

EFV/FTC/TDF

Gilead

Approved

1 7

Biological Check-up

UUniversity Hospital, Bordeaux

Phase 2

1 8

MMH-MAP

MMateria Medica Holding

Phase 3

1 9

Feraheme

AAzurity Pharmaceuticals

Phase 1

1 10

Lithium Treatment

VVA Office of Research and Development

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tenofovir Disoproxil Fumarate2 trials

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01309243·799 enrolled

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Completed· Gilead logo

Gilead·Phase 3·NCT02345226·881 enrolled

Itching1 trial

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Completed· Gilead logo

Gilead·Phase 3·NCT01815736·1,443 enrolled

Cognitive Disorder1 trial

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

Completed·FFelipe Garcia·Phase 4·NCT01529749·48 enrolled

Efficacy and Safety1 trial

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed· Gilead logo

Gilead·Phase 1/2·NCT01565889·52 enrolled

Bone Health1 trial

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01403051·167 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for EFV/FTC/TDF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EFV/FTC/TDF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EFV/FTC/TDF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Gilead

EFV/FTC/TDF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tenofovir Disoproxil Fumarate2 trials

Itching1 trial

Cognitive Disorder1 trial

Efficacy and Safety1 trial

Bone Health1 trial

References

Drug Info

Quick Facts

Related News